Nyxoah Advances Genio Neurostimulator for OSA in Q3
Nyxoah SA reported a successful third quarter with clinical trial progress for its Genio neurostimulator system for the treatment of obstructive sleep apnea.
Nyxoah SA reported a successful third quarter with clinical trial progress for its Genio neurostimulator system for the treatment of obstructive sleep apnea.
A patient success story highlights how the remedē System, an FDA-approved implantable stimulator for central sleep apnea, enhanced the quality of life for Maryland's James Drake, 74.
The update includes an increase on the upper limit of the apnea-hypopnea Index and raises the body mass index warning in the labeling.
Inspire Medical Systems Inc reported second-quarter business results, marked by a series of US Food and Drug Administration regulatory approvals and submissions.
Read MoreThe newly appointed chief medical officer will serve full-time on Inspire’s executive leadership team and lead the company’s medical and clinical affairs functions.
Read MoreProSomnus announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation in treating patients with severe OSA.
Read MoreSleep apnea is common in children with Down syndrome. Sleep experts weigh in on what’s new in diagnosing and treating this patient population.
Read MoreWith further development, the technology could allow people to control dream plots and induce lucid dreams, according to REMspace researchers.
Read MoreThe company has completed all 115 implants in the DREAM trial and expects full 12-month data in the first quarter of next year.
Read MoreInspire Medical Systems Inc, a medical technology company focused on the development of solutions...
Read MoreNasdaq recognized the milestone by congratulating Signifier Medical on the Nasdaq Tower in Times Square, New York.
Read MoreThe reimbursement approval provides a pathway to open additional Inspire implanting centers in Belgium, while expanding access to care, according to Inspire Medical Systems.
Read MoreThe clinical and regulatory milestones bring Nyxoah closer to offering its Genio neurostimulator solution to OSA patients in the US, according to the company.
Read MoreThe FDA has granted Inspire Medical Inc Breakthrough Device Designation for a potential increase in the upper limit of AHI and BMI for patients to be eligible for Inspire Upper Airway Stimulation for obstructive sleep apnea.
Read MoreNew launches and upcoming plans from ZOLL Respicardia, Inspire Medical, and LivaNova make patient data more accessible and trackable.
Read MoreThis full-body MRI approval expands the Inspire use labeling that previously allowed only head, neck, and extremity MRI scans.
Read MoreGenio 2.1’s upgrades are entirely related to the external components of the Genio system, as the implantable stimulator remains unchanged.
Read MoreOne key factor driving Inspire’s growth achieved during Q1 was the performance of the company’s Advisor Care Program.
Read More